|Videos|July 23, 2016

Will We See More Cases of Antibiotic-resistant Superbugs in the US?

Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, President, Society of Infectious Diseases Pharmacists, in light of the recent antibiotic resistant superbug, shares if we will see more cases of antibiotic resistance in the United States.

Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, President, Society of Infectious Diseases Pharmacists, in light of the recent antibiotic resistant superbug, shares if we will see more cases of antibiotic resistance in the United States.

Interview Transcript (slightly modified for readability)

“It is inevitable that we will see more resistant bacteria and eventually outbreaks in the United States. [Escherichia] coli is normal flora, so the biggest concern here is that this can become something that just colonizes people, [like] they have all the time. When antibiotic-resistance doesn’t cost the bacteria a lot of energy, or lead to problems in it, then that resistance can spread fairly easily. We don’t know exactly if [the Pennsylvania Superbug] is one of those or not, but should that be the case, then it’s very likely to spread.

We already have resistant bacteria spreading throughout the country and causing more common infections than used to. I think that one of the best things that [the] CDC has done is put the spotlight on our problem of antimicrobial resistance, particularly with their release of a report in 2013 describing the antibiotic resistance threats in the United States, where they highlighted the off-quoted numbers that 2 million people a year are infected in the United States with an antibiotic-resistant bacteria and over 23,000 die every year from it. That doesn’t include [the] over 10,000 who die from C. diff infections each year. The numbers are pretty impressive.

I think a lot of the media is grabbing on to this and running with ‘does this herald the end of antibiotics?’ and I don’t think that is the case, but it is a concerning indicator that we have reached the point that there are untreatable infections. I don’t think that will become the norm for most infections, probably ever, but it is the beginning of a slippery slope that we’ve already been going down.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.